Dose Selection in a Pandemic: A Framework Informed by the FDA Animal Rule

Dose Selection in a Pandemic: A Framework Informed by the FDA Animal Rule

Bibliographic Details
Main Authors:	Kunyi Wu, Kimberly L. Bergman
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Clinical and Translational Science
Online Access:	https://doi.org/10.1111/cts.12936

Similar Items

FDA Experience with Medical Countermeasures under the Animal Rule
by: Paul Aebersold
Published: (2012-01-01)

Understanding the new FDA pregnancy and lactation labeling rules
by: Collin M. Blattner, D.O.
Published: (2016-03-01)

Rabbitpox in New Zealand White Rabbits: A Therapeutic Model for Evaluation of Poxvirus Medical Countermeasures Under the FDA Animal Rule
by: Mark R. Perry, et al.
Published: (2018-10-01)

FDA PLATO deaths list challenges aspirin dose—ticagrelor interaction
by: Victor Serebruany, et al.
Published: (2021-09-01)

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
by: Peter Marks
Published: (2019-09-01)

The next forum for unraveling FDA off-label marketing rules: State and federal legislatures.
by: Michael S Sinha, et al.
Published: (2018-05-01)

Development and Characterization of Ectromelia Virus-Moscow in the BALB/c Mouse Model for Smallpox Therapeutic and Prophylaxis Drug Efficacy Testing Under the FDA Animal Rule
by: Huettner, Lauren E.
Published: (2014)

Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioequivalence testing
by: Demana, P H, et al.
Published: (1997)

FDA draft guidance on compounding animal drugs from bulk drug substances: a commentary
by: Adel H. Karara
Published: (2016-07-01)

Characterization of Dosing Recommendations for Renal Impairment Provided in Prescribing Information Since the FDA Guidance Document: Have the Recommendations Become More Clear?
by: Parades, Karen, et al.
Published: (2015)

The Consistency of Panoramic Radiography Selection Criteria by Dentists in Tehran with the FDA Guidelines
by: Sima Nikneshan, et al.
Published: (2013-10-01)

2018 FDA Tides Harvest
by: Danah Al Shaer, et al.
Published: (2019-04-01)

2017 FDA Peptide Harvest
by: Othman Al Musaimi, et al.
Published: (2018-05-01)

FDA commissioner Gottlieb resigns
by: Robbins RA
Published: (2019-03-01)

Plasma preparation to measure FDA‐approved protein markers by selected reaction monitoring
by: Olga I. Kiseleva, et al.
Published: (2015-12-01)

Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
by: Amira Osman, et al.
Published: (2018-04-01)

Electronic trading, liquidity and information efficiency : evidence from the Montreal exchange
by: Wang, Kunyi
Published: (2007)

Clustering and Dispatching Rule Selection Framework for Batch Scheduling
by: Gilseung Ahn, et al.
Published: (2020-01-01)

FDA approved ready to use phenylephrine
by: Pradeep Kumar Bhatia, et al.
Published: (2021-01-01)

Why did the FDA approve these advertisements?
by: David Oaks
Published: (2006-02-01)

Drugs, Devices, and the FDA: Part 2
by: Gail A. Van Norman, MD
Published: (2016-06-01)

Drugs, Devices, and the FDA: Part 1
by: Gail A. Van Norman, MD
Published: (2016-04-01)

Insights from FDA Warning Letters
Published: (2010-01-01)

Gottlieb, the FDA and dumbing down medicine
by: Robbins RA
Published: (2017-04-01)

FDA Public Advisory for Nevirapine (Viramune)
by: Editorial Office
Published: (2005-05-01)

Assessing biodiversity profile through FDA
by: Tonio Di Battista, et al.
Published: (2013-10-01)

Announcement Effect of Drug Approvals by FDA
by: Ting, Hsiu Wen, et al.
Published: (2008)

An FDA Implementation of Multi-prototype Classification
by: Jian-Li Kuo, et al.
Published: (2010)

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
by: Felix W. Frueh, et al.
Published: (2013-06-01)

In silico Selection and Experimental Validation of FDA-Approved Drugs as Anti-quorum Sensing Agents
by: Marta Mellini, et al.
Published: (2019-10-01)

Do investors value the FDA orphan drug designation?
by: Kathleen L. Miller
Published: (2017-06-01)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
by: Hao Zhong, et al.
Published: (2018-12-01)

Chemical Crosslinking of 6FDA-ODA and 6FDA-ODA:DABA for Improved CO2/CH4 Separation
by: Mohd Zamidi Ahmad, et al.
Published: (2018-08-01)

Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines
by: Nacif Marcelo S, et al.
Published: (2012-02-01)

Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioeqivalence testing [authors' reply in Letters to the Editor]
by: Smith, E W, et al.
Published: (1998)

2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
by: Othman Al Musaimi, et al.
Published: (2021-02-01)

Acrylamide in Food – EU versus FDA Approaches
by: Gabriel Mustăţea, et al.
Published: (2015-11-01)

2019 FDA TIDES (Peptides and Oligonucleotides) Harvest
by: Danah Al Shaer, et al.
Published: (2020-03-01)

Additively manufactured medical products – the FDA perspective
by: Matthew Di Prima, et al.
Published: (2016-12-01)

Correction/clarification about FDA review documents.
by: Erick Turner
Published: (2005-12-01)